TY  - JOUR
A1  - Schmitt, Jana
A1  - Keller, Andreas
A1  - Nourkami-Tutdibi, Nasenien
A1  - Heisel, Sabrina
A1  - Habel, Nunja
A1  - Leidinger, Petra
A1  - Ludwig, Nicole
A1  - Gessler, Manfred
A1  - Graf, Norbert
A1  - Berthold, Frank
A1  - Lenhof, Hans-Peter
A1  - Meese, Eckart
T1  - Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients
JF  - PLoS ONE
N2  - Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.
KW  - Heparan-sulfate
KW  - N-Myc
KW  - Serum autoantibodies
KW  - Suppressors EXT1
KW  - Neuro-blastoma
KW  - Allelic loss
KW  - Lung-cancer
KW  - Children
KW  - Amplification
KW  - Therapy
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133794
VL  - 6
IS  - 12
ER  - 
TY  - JOUR
A1  - Wegert, Jenny
A1  - Bausenwein, Sabrina
A1  - Kneitz, Susanne
A1  - Roth, Sabine
A1  - Graf, Norbert
A1  - Geissinger, Eva
A1  - Gessler, Manfred
T1  - Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro
N2  - Background: Wilms tumor (WT) is one of the most common malignancies in childhood. With current therapy protocols up to 90% of patients can be cured, but there is still a need to improve therapy for patients with aggressive WT and to reduce treatment intensity where possible. Prior data suggested a deregulation of the retinoic acid (RA) signaling pathway in high-risk WT, but its mode of action remained unclear. Results: The association of retinoid signaling and clinical parameters could be validated in a large independent tumor set, but its relevance in primary nephrectomy tumors from very young children may be different. Reduced RA pathway activity and MYCN overexpression were found in high risk tumors as opposed to tumors with low/ intermediate risk, suggesting a beneficial impact of RA especially on advanced WT. To search for possible modes of action of retinoids as novel therapeutic options, primary tumor cell cultures were treated in vitro with all-trans-RA (ATRA), 9cis-RA, fenretinide and combinations of retinoids and a histone deacetylase (HDAC) inhibitor. Genes deregulated in high risk tumors showed opposite changes upon treatment suggesting a positive effect of retinoids. 6/7 primary cultures tested reduced proliferation, irrespective of prior RA signaling levels. The only variant culture was derived from mesoblastic nephroma, a distinct childhood kidney neoplasm. Retinoid/HDAC inhibitor combinations provided no synergistic effect. ATRA and 9cis-RA induced morphological changes suggestive of differentiation, while fenretinide induced apoptosis in several cultures tested. Microarray analysis of ATRA treated WT cells revealed differential expression of many genes involved in extracellular matrix formation and osteogenic, neuronal or muscle differentiation. The effects documented appear to be reversible upon drug withdrawal, however. Conclusions: Altered retinoic acid signaling has been validated especially in high risk Wilms tumors. In vitro testing of primary tumor cultures provided clear evidence of a potential utility of retinoids in Wilms tumor treatment based on the analysis of gene expression, proliferation, differentiation and apoptosis.
KW  - Krebs
KW  - Wilms tumor
KW  - nephroblastoma
KW  - primary tumor cell culture
KW  - tumor model
KW  - retinoic acid
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69137
ER  -